NCT02217956View on ClinicalTrials.gov

Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Ovarian AdenocarcinomaFallopian Tube AdenocarcinomaPrimary Peritoneal Carcinoma
Interventions
DRUG

Cisplatin

DRUG

Bevacizumab

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT02217956 - Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma | Biotech Hunter | Biotech Hunter